Our mission is to become the world’s leading provider of cutting-edge diagnostic tools for early detection of skin cancer, through continuous application of ground-breaking technologies and innovative distribution models.
ScreenCancer was established in Norway in 2007, and consists of 14 specialists in skin cancer screening, optical technologies and business development for the healthcare industry.
ScreenCancer’s tele-dermatology services can be found in more than 300 European pharmacies, spread throughout Norway, Sweden, UK, Ireland and France. The services include “Mole Scanning Service” and “Skin Scanning Service”, which offer rapid expert dermatologist assessment of any moles or skin lesions causing concern on a drop-in basis at the customers’ local pharmacy. The services are mainly distributed through a global distribution agreement with pharmacy chain, the Walgreens Boots Alliance.
Since its inception, ScreenCancer has raised more than €4 million from private investors, and is today fully owned by the parent company, DeepX Health. ScreenCancer constitutes one of three companies in DeepX Health’s portfolio of technology and healthcare focused firms. For more information, please visit: www.screencancer.com